| 000 | 01874 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513144046.0 | ||
| 264 | 0 | _c19980626 | |
| 008 | 199806s 0 0 eng d | ||
| 022 | _a1078-8956 | ||
| 024 | 7 |
_a10.1038/nm0698-691 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKato, M | |
| 245 | 0 | 0 |
_aPhysiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. _h[electronic resource] |
| 260 |
_bNature medicine _cJun 1998 |
||
| 300 |
_a691-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aBinding Sites _xphysiology |
| 650 | 0 | 4 |
_aExudates and Transudates _xchemistry |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xpharmacology |
| 650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aGlucuronidase |
| 650 | 0 | 4 |
_aGlycoside Hydrolases _xpharmacology |
| 650 | 0 | 4 |
_aHeparin _xpharmacology |
| 650 | 0 | 4 |
_aHeparitin Sulfate _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xdrug effects |
| 650 | 0 | 4 |
_aMitogens _xmetabolism |
| 650 | 0 | 4 |
_aOligosaccharides _xpharmacology |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 |
_aProteoglycans _xdrug effects |
| 650 | 0 | 4 | _aReceptor Protein-Tyrosine Kinases |
| 650 | 0 | 4 | _aReceptor, Fibroblast Growth Factor, Type 1 |
| 650 | 0 | 4 |
_aReceptors, Fibroblast Growth Factor _xmetabolism |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 | _aSyndecan-1 |
| 650 | 0 | 4 | _aSyndecans |
| 650 | 0 | 4 |
_aWounds and Injuries _xmetabolism |
| 700 | 1 | _aWang, H | |
| 700 | 1 | _aKainulainen, V | |
| 700 | 1 | _aFitzgerald, M L | |
| 700 | 1 | _aLedbetter, S | |
| 700 | 1 | _aOrnitz, D M | |
| 700 | 1 | _aBernfield, M | |
| 773 | 0 |
_tNature medicine _gvol. 4 _gno. 6 _gp. 691-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/nm0698-691 _zAvailable from publisher's website |
| 999 |
_c9590376 _d9590376 |
||